Celestica's HealthTech Portfolio Faces Valuation Pressure Amid Rising Estimates
Celestica's medical device manufacturing arm is driving significant upward revisions in earnings forecasts, yet the stock trades at a premium to industry averages.
Celestica Inc. is leveraging its global supply chain to serve the expanding market for surgical robotics and diagnostic instruments. The company provides precision manufacturing and systems integration for medical device makers, focusing on product quality and regulatory compliance. This position allows Celestica to capture growth from the digital health sector, including connected medical products and patient monitoring systems.
Despite a strong operational footprint, Celestica shares have risen 39.1% over the past year, lagging behind the broader industry growth of 50.1%. The stock currently carries a forward price-to-earnings ratio of 20.71, which is higher than the industry average of 19.66. This valuation gap suggests investors are pricing in continued expansion in the HealthTech segment despite the relative underperformance against sector peers.
Earnings Estimates Show Sharp Upward Revisions
Financial analysts have significantly increased their expectations for the company's future profitability. Estimates for 2026 earnings per share have climbed 11.4% to $11.32 over the past 60 days. The revision is even more pronounced for the following year, with 2027 earnings estimates jumping 30.2% to $19.01 per share. These adjustments reflect confidence in the company's ability to convert its HealthTech portfolio into tangible revenue growth.
Competitive Landscape Includes Jabil And Sanmina
Celestica competes directly with major electronics manufacturing services providers like Jabil and Sanmina. Jabil focuses on connected health and drug-delivery technologies, utilizing its supply chain to help clients launch new products efficiently. Sanmina specializes in cardiovascular care and robotic surgery, combining engineering and manufacturing services to support medical technology development. Celestica differentiates itself through its specific expertise in diagnostics and surgical technologies, aiming to retain clients through end-to-end lifecycle support.
Market Position Driven By Regulatory Complexity
The complexity of producing regulated medical devices creates a barrier to entry that favors established players. Celestica utilizes its global manufacturing footprint to manage these complex production needs, enhancing reliability for customers. As adoption of smart medical devices increases, the demand for partners who can navigate regulatory requirements while maintaining cost efficiency is expected to rise. This structural advantage supports the company's long-term revenue prospects in the healthcare sector.
